Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1997016201) ANGIOTENSIN IV AND ANALOGS AS REGULATORS OF FIBRINOLYSIS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/016201 International Application No.: PCT/US1996/013804
Publication Date: 09.05.1997 International Filing Date: 27.08.1996
Chapter 2 Demand Filed: 13.05.1997
IPC:
A61K 38/00 (2006.01) ,A61K 38/08 (2006.01) ,A61K 38/55 (2006.01) ,C07K 5/083 (2006.01) ,C07K 5/097 (2006.01) ,C07K 7/14 (2006.01) ,C07K 16/26 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08
Peptides having 5 to 11 amino acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
55
Protease inhibitors
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
5
Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
04
containing only normal peptide links
08
Tripeptides
083
the side chain of the first amino acid being acyclic, e.g. Gly, Ala
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
5
Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
04
containing only normal peptide links
08
Tripeptides
097
the first amino acid being heterocyclic, e.g. Pro, His, Trp, e.g. thyroliberin, melanostatin
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
7
Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04
Linear peptides containing only normal peptide links
14
Angiotensins; Related peptides
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
26
against hormones
Applicants:
BRIGHAM & WOMEN'S HOSPITAL [US/US]; 75 Francis Street Boston, MA 02115, US
WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION [US/US]; N.E. 1615 Eastgate Boulevard Pullman, WA 99163, US
Inventors:
VAUGHAN, Douglas, E.; US
HARDING, Joseph, W.; US
Agent:
FREEMAN, John, W.; Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110-2804, US
Priority Data:
08/550,17430.10.1995US
Title (EN) ANGIOTENSIN IV AND ANALOGS AS REGULATORS OF FIBRINOLYSIS
(FR) ANGIOTENSINE IV ET ANALOGUES D'ANGIOTENSINE IV UTILES COMME REGULATEURS DE LA FIBRINOLYSE
Abstract:
(EN) Angiotensin IV (VAL-TYR-ILE-HIS-PRO-PHE), a degradation product of angiotensin II previously thought to be inactive, interacts directly with endothelial cells to induce expression of PAI-1 and thereby to inhibit clot lysis attributable to endogenous t-PA. Moreover, angiotensin IV does not effect substantial physiological changes (vasoconstriction, increased blood pressure, etc.) characteristic of angiotensin II. Fibrinolysis is promoted by reducing the amount or the effect of angiotensin IV. Fibrinolysis is inhibited by providing enhanced angiotensin IV. Methods of screening candidates for antagonizing angiotensin IV are also disclosed.
(FR) L'angiotensine IV (VAL-TYR-ILE-HIS-PRO-PHE) issue de la décomposition de l'angiotensine II et supposée inactive jusqu'à présent, interagit directement avec les cellules endothéliales pour induire l'expression de PAI-1 et inhiber par conséquent la lyse des caillots attribuable au T-PA endogène. En outre, l'angiotensine IV ne produit pas de modifications physiologiques sensibles (vasoconstriction, pression sanguine accrue, etc...) caractéristiques de l'angiotensine II. On améliore la fibrinolyse en réduisant la quantité ou l'effet de l'angiotensine IV. Des procédés de recherche par criblage de candidats capables d'avoir une action antagoniste sur l'angiotensine IV sont également décrits.
Designated States: AU, CA, JP
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
AU1996068617